USF-LVHN SELECT
T-cell receptor anti-CMV CDR3s from bone marrow samples are associated with a worse overall survival for recurrent acute myeloid leukemia.
Publication/Presentation Date
1-1-2026
Abstract
We assessed the relationship of AML patient outcomes and T-cell receptor (TCR) recombination reads representing known anti-viral TCR sequences. TCR complementary determining region-3's (CDR3s) were obtained from the pediatric TARGET-AML dataset, and the TCR CDR3s representing bone marrow samples of primary and recurrent disease were matched to anti-viral TCR CDR3s. The patients representing the presence of the anti-viral CDR3s were then assessed for overall survival (OS). Patients with anti-CMV TCR CDR3s from bone marrow samples representing recurrent AML showed a significant decrease in OS probability. Decreases in OS probabilities were also observed for patients with anti-Epstein Barr Virus (EBV) TCR CDR3s obtained from recurrent AML, bone marrow samples. Overall, this study raises the question of whether there is a relationship between viral infections, or the basic impact of anti-viral inflammation, and outcomes in pediatric AML?
Volume
25
First Page
100580
Last Page
100580
ISSN
2213-0489
Published In/Presented At
Paul, S., Aboujaoude, M. T., Barker, V. R., Hudock, T. R., Sahoo, A., & Blanck, G. (2026). T-cell receptor anti-CMV CDR3s from bone marrow samples are associated with a worse overall survival for recurrent acute myeloid leukemia. Leukemia research reports, 25, 100580. https://doi.org/10.1016/j.lrr.2026.100580
Disciplines
Medical Education | Medicine and Health Sciences
PubMedID
41908976
Department(s)
USF-LVHN SELECT Program, USF-LVHN SELECT Program Students
Document Type
Article